Viking Therapeutics Inc. (VKTX)

Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies.

Investing successfully in biopharmaceutical companies can sometimes require complicated calculations worthy of Albert Einstein's brain. That's because picking the right ones involves a variation of th...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

While most investors pile into Eli Lilly (LLY 2.95%) or flee from struggling Novo Nordisk (NVO 2.48%), they're missing a compelling opportunity in the clinical-stage space. Novo recently lost nearly $...

Recent history has, once again, demonstrated that relatively small biotech companies can see their shares soar significantly on positive developments. Summit Therapeutics' stock is up by more than 2,0...

The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other produ...

Explore the exciting world of Viking Therapeutics (VKTX 0.28%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into ma...

Viking Therapeutics' stock has outperformed the S&P 500 since its April lows, marking a solid turnaround. The company's dual-track approach (injectables and oral) for VK2735 positions it well against ...

Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Company Participants Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer C...